Experimental pill promises new hope for deadly pancreatic cancer
Reported byNPR ↗·Sourced by Goodlede
Randomized study of 500 patients showed the drug daraxonrasib nearly doubled median survival time to 13.2 months vs 6.7 months for chemotherapy, with fewer severe side effects; published in New England Journal of Medicine and presented at ASCO meeting
Does not prove cure; only tested on advanced metastatic pancreatic cancer patients whose prior treatment had failed; long-term survival and broader applicability remain unknown
Goodlede runs a two-pass source check on every story: one pass finds it, a second skeptical pass re-verifies the claim and writes what it doesn’t prove. This is a source check, not an independent fact-check — confirm anything important at the link above.
Read the full story at NPR
Read original story ↗↻ Refreshed daily
More good news, verified daily.
Goodlede finds recent positive developments across science, nature, rights, and human achievement — and re-verifies each one before it appears. No hype, no roundups, no PR wires.
© 2026 Wag Media, LLC
More from Goodlede